Company intelligence
Precision Epigenomics
Advanced Solutions to Early Cancer Diagnostics
Medical and Diagnostic Laboratories
Tucson, US
31 employees
7 public signals
Verified activity
Signals from Precision Epigenomics
7 published signals
Research & Knowledge
Precision Epigenomics released the results of its most recent data on the EPISEEK multi-cancer early detection test.
Reported by Jannalee Johnson
Presence & Recognition
Precision Epigenomics honors all First Responders at the FRI 2026 event.
Reported by Jannalee Johnson
Research & Knowledge
Precision Epigenomics published the results of a new study showing EPISEEK outperforms alternative liquid biopsy tests across the board in sensitivity, specificity, and turnaround time.
Reported by Precision Epigenomics
Research & Knowledge
Precision Epigenomics published new clinical validation data showing that EPISEEK significantly outperforms market alternatives across every critical operational and clinical metric.
Reported by Precision Epigenomics
Products & Services
Precision Epigenomics announced the EPISEEK multi-cancer early detection test.
Reported by Jannalee Johnson
Research & Knowledge
Precision Epigenomics shared new clinical validation data showing how EPISEEK multi-cancer early detection leads in early stage sensitivity data.
Reported by Jannalee Johnson
Research & Knowledge
Precision Epigenomics announced the results of a new study showing EPISEEK outperforms alternative liquid biopsy tests across the board.
Reported by Jannalee Johnson